{
"id":"mk19_a_on_q015",
"number":15,
"bookId":"on",
"correctAnswer":"B",
"title":"Question 15",
"stimulus":[
{
"type":"p",
"hlId":"19a758",
"children":[
"A 62-year-old woman undergoes follow-up evaluation for epithelial ovarian cancer. Seven months ago, she underwent surgical debulking with optimal cytoreduction, and the primary tumor and visible metastases were all resected. Surgery was followed by platinum-taxane chemotherapy. There has been no evidence of disease recurrence. Germline genetic testing revealed a ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRCA1"
]
},
" mutation. Her medical history is otherwise unremarkable, and she takes no medications."
]
},
{
"type":"p",
"hlId":"64932f",
"children":[
"On physical examination, vital signs are normal. There is a well-healed laparotomy incision."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"1fa31e",
"children":[
"Which of the following is the most appropriate additional treatment for this patient?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Irradiation"
}
},
{
"letter":"B",
"text":{
"__html":"Poly (ADP-ribose) polymerase inhibitor therapy"
}
},
{
"letter":"C",
"text":{
"__html":"Second course of chemotherapy"
}
},
{
"letter":"D",
"text":{
"__html":"No additional treatment"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"defcc0",
"children":[
"Women with advanced ovarian cancer and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRCA"
]
},
" mutations who achieve some response to platinum-based chemotherapy should receive subsequent maintenance therapy with a poly (ADP-ribose) polymerase inhibitor."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"df3df0",
"children":[
"This patient has advanced epithelial ovarian cancer and a germline ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRCA1"
]
},
" mutation and should receive maintenance therapy with a poly (ADP-ribose) polymerase (PARP) inhibitor (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"). She had optimal debulking, defined as residual tumor deposits less than 1 cm in size, which is associated with improved outcomes. The addition of adjuvant platinum-taxane chemotherapy also improves disease-free and overall survival. For ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRCA1"
]
},
" or ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRCA2"
]
},
" mutation carriers with platinum-sensitive disease (a disease-free interval greater than 6 months), the addition of a maintenance PARP inhibitor following the completion of adjuvant chemotherapy is associated with substantial improvements in progression-free survival. PARPs are involved in repair of single-strand breaks. PARP inhibition leads to DNA breaks that activate homologous recombination (HR) repair. Patients with ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRCA"
]
},
" mutations have defective HR repair, which results in an error-prone repair mechanism that cannot repair these breaks, leading to cell death. In this way, PARP inhibitors are cytotoxic for cancer cells, especially those with a germline or somatic ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRCA1/2"
]
},
" mutation. Maintenance PARP inhibition is also recommended for patients without ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRCA1/2"
]
},
" mutations, but benefits in progression-free survival are lesser."
]
},
{
"type":"p",
"hlId":"c9369b",
"children":[
"Irradiation (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") does not play a role in the adjuvant management of patients with advanced ovarian cancer. Ovarian cancer has a tendency to disseminate within the peritoneal cavity along the peritoneal surface and requires a systemic therapy approach following initial surgery."
]
},
{
"type":"p",
"hlId":"4b0bba",
"children":[
"Repeat treatment with platinum-taxane chemotherapy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is not recommended in this patient who has responded to initial therapy and has no evidence of recurrent disease. Platinum-based chemotherapy is indicated in patients who relapse 6 months or longer after initial therapy and are more likely to respond to a second course of platinum-based chemotherapy than those who relapse before 6 months. This patient has responded to initial therapy, and the addition of maintenance PARP inhibitor therapy further improves progression-free survival and delays the need for a second course of platinum-based chemotherapy."
]
},
{
"type":"p",
"hlId":"8c365b",
"children":[
"No additional therapy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is inappropriate for this patient with advanced epithelial ovarian cancer. The addition of a PARP inhibitor results in substantial improvements in progression-free survival and delays the need for a second course of chemotherapy."
]
}
],
"relatedSection":"mk19_a_on_s3_4",
"objective":{
"__html":"Treat a patient with germline <i>BRCA1</i> mutation and advanced ovarian cancer."
},
"references":[
[
"González-Martín A, Pothuri B, Vergote I, et al; PRIMA/ENGOT-OV26/GOG-3012 Investigators. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381:2391-2402. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31562799",
"target":"_blank"
},
"children":[
"PMID: 31562799"
]
},
" doi:10.1056/NEJMoa1910962"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":2,
"B":29,
"C":6,
"D":63,
"E":0
},
"hlIds":[
"19a758",
"64932f",
"1fa31e",
"defcc0",
"df3df0",
"c9369b",
"4b0bba",
"8c365b"
]
}